A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus
Phase of Trial: Phase IV
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Prednisone (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms RIFLE
- Sponsors AMPEL BioSolutions
- 26 Sep 2017 Planned End Date changed from 1 May 2018 to 1 Jun 2018.
- 26 Sep 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
- 28 Mar 2017 Status changed from planning to recruiting.